Aug 6, 2026 07:24AM
Aug 6, 2026 07:00AM
Jul 30, 2026 08:00AM
May 11, 2026 07:54AM
May 11, 2026 07:30AM
Feb 26, 2026 01:31PM
Feb 26, 2026 07:35AM Intellia Therapeutics (NTLA) Tops Q4 EPS by 13c
Feb 26, 2026 07:30AM
Feb 19, 2026 07:30AM
Nov 6, 2025 04:29PM
Nov 6, 2025 04:00PM
Oct 28, 2025 04:23AM
Aug 8, 2025 06:24AM
Aug 7, 2025 07:33AM Intellia Therapeutics (NTLA) Tops Q2 EPS by 5c
Aug 7, 2025 07:30AM
Jul 31, 2025 07:30AM
May 8, 2025 07:31AM
May 8, 2025 07:30AM
May 1, 2025 07:30AM
Feb 27, 2025 03:04PM
Feb 27, 2025 07:30AM Intellia Therapeutics (NTLA) Tops Q4 EPS by 7c
Feb 27, 2025 07:30AM
Feb 20, 2025 07:30AM
Nov 11, 2024 07:52AM
Nov 7, 2024 08:21AM
Nov 7, 2024 07:30AM
Oct 31, 2024 07:30AM
Oct 7, 2024 07:31AM Intellia Therapeutics (NTLA) Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
Oct 7, 2024 07:30AM
Aug 8, 2024 07:30AM
Aug 8, 2024 07:30AM
Aug 1, 2024 07:30AM
May 9, 2024 07:37AM
May 9, 2024 07:30AM
May 2, 2024 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
Feb 23, 2024 09:23AM
Feb 22, 2024 07:37AM
Feb 22, 2024 07:30AM
Feb 14, 2024 07:30AM
Nov 9, 2023 07:31AM
Nov 9, 2023 07:30AM
Oct 26, 2023 07:30AM Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earni
Oct 18, 2023 07:02AM
Oct 18, 2023 07:00AM
Aug 3, 2023 07:34AM
Aug 3, 2023 07:30AM
Jul 27, 2023 07:30AM
May 4, 2023 08:19AM
May 4, 2023 07:30AM Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
Apr 27, 2023 07:30AM

1,222,640 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All